Daniel Grill|Tetra Images|Getty Images
Altimmune on Wednesday stated its speculative drug assisted clients shed weight however likewise reduced the loss of muscle mass in a midstage trial, a finding that might set it apart in a possibly congested market.
Altimmune is among a number of smaller sized biotech business that are pressing to contend straight with Novo Nordisk and Eli Lilly in the growing weight-loss drug area, or to get scooped up by bigger drugmakers that can assist bring their treatments to market.
The outcomes are an early indication that the biotech business can attend to a significant issue around those treatments, which have actually drawn relentless need and financier interest over the in 2015.
Some health specialists have actually stated that weight problems drugs might diminish crucial muscle mass, which might raise the danger of injuries and reduce strength.
But in Altimmune’s late-stage trial, more than 74% of the weight that clients lost after taking the business’s weekly injection originated from fat tissue and just 25.5% originated from lean mass, according to the business. Those outcomes resemble those frequently seen with diet plan and workout programs for weight-loss.
Patients who took a 2.4-milligram dosage of Altimmune’s drug weekly for 48 weeks lost 15.6% of their weight usually in the trial, with weight-loss continuing at the end of treatment, the business stated.
The business initially revealed that weight-loss information on the drug, called pemvidutide, inNovember
“Preservation of lean mass throughout weight-loss is crucial, because extreme loss of lean mass has actually been connected with unfavorable results, such as [a gradual loss of muscle mass and strength] and bone fractures, particularly in females and the senior,” Altimmune Chief Medical Officer Scott Harris stated in a declaration. “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.”
In a medical trial on semaglutide, the active component in Novo Nordisk’s Ozempic and Wegovy, scientists analyzed the loss of lean muscle mass in a subgroup of about 140 clients. On average, individuals lost about 15 pounds of lean muscle and 23 pounds of fat throughout the 68- week trial.
Those results recommend a greater rate of lean mass decrease than in Altimmune’s trial. Still, Altimmune requires to carry out late-stage trials on its drug, so it’s prematurely to state just how much of an edge it has more than existing weight-loss treatments.
The 2 drugs likewise work in a different way.
Semaglutide imitates a hormonal agent produced in the gut called GLP-1 to reduce an individual’s cravings. Meanwhile, Altimmune’s drug triggers GLP-1 and another gut hormonal agent called glucagon, which increases energy expense.
Altimmune is likewise establishing that drug to deal with a typical type of liver illness called metabolic dysfunction-associated steatohepatitis, or MASH.
Other makers of weight problems drugs are likewise attempting to assist clients keep muscle mass.
For example, Eli Lilly is evaluating whether integrating its weight-loss drug with a monoclonal antibody from Versanis Bio may assist clients drop weight while protecting muscle mass. The pharmaceutical giant just recently gotten Versanis, which belongs to a slate of business targeting the muscle-loss element of weight-loss.
